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Background: Atherosclerotic cardiovascular disease is one of the major diseases that seriously impacts human
health. Combined drug therapy may be efficacious in delaying the occurrence of cardiovascular events.
Aim: The current study was designed to investigate whether combined use of probucol (an anti-oxidant agent) with
cilostazol (a platelet aggregation inhibitor) would increase the inhibitory effect of statins (a lipid-lowering agent) on
atherosclerosis in moderately hypercholesterolemic rabbits.
Methods and Results: Thirty Japanese white rabbits were fed with a high cholesterol diet for 12 weeks, which was
supplemented with either 0.005 % atorvastatin alone or 0.005 % atorvastatin plus 0.3 % probucol and 0.3 % cilostazol.
Except for high-density lipoprotein cholesterol, no difference was found in plasma lipids among vehicle, statin, and the
combined treatment group. However, atherosclerotic lesions were significantly reduced by statin treatment compared
with vehicle. Moreover, we found that the anti-atherogenic effect of statin was further enhanced by the combined
treatment, which was due to increased anti-inflammatory and anti-oxidant properties.
Conclusions: These data demonstrated that combined drug treatment exhibits potent athero-protective effects via
pleiotropic functions, such as anti-inflammatory and anti-oxidative stress, which is independent of the lipid-lowering effect.
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Atherosclerotic cardiovascular disease (ASCVD) is the
foremost cause of disability and mortality in both devel-
oped and developing countries [1–3]. Atherosclerosis is a
multifactorial disease and progresses slowly throughout
the human life; therefore treatment of atherosclerosis re-
quires many therapeutic strategies. Statins, hydroxylmethyl
glutaryl coenzyme A reductase inhibitors, are widely used
for treating hyperlipidemia [4–7]. Although statins are the
first choice for treatment of atherosclerosis [8–11], there
are still many patients who are not responsive to statins.
Actually, statins intolerance is frequently encountered in
clinical practice [12, 13]. Therefore, it may be practical to* Correspondence: bailiang0922@mail.xjtu.edu.cn
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creativecommons.org/publicdomain/zero/1.0/consider the combined use of statins with other drugs for
those unresponsive patients. Previous studies have shown
that atorvastatin combined with probucol exhibited a stron-
ger anti-atherogenic effect than single drug treatment [14].
Probucol, a diphenolic compound with anti-inflammatory
and anti-oxidant properties, can reduce atherosclerosis and
restenosis in coronary arteries [15, 16]. Cilostazol, an in-
hibitor of type 3 phosphodiesterase, is widely used for
treating thrombotic vascular disease and exerts anti-
platelet activity via suppression of cyclic adenosine
monophosphate degradation [17, 18]. Our previous
studies found that the combined use of probucol with
cilostazol has a greater anti-atherogenic effect than
single probucol treatment [19]. Rabbits fed with a
cholesterol diet are readily to develop atherosclerotic
lesions, which mimics the lesions observed in ASCVD
patients [20]. However, whether combination of sta-
tins with probucol and cilostazol has an add-on effecticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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rabbits is still unknown.
In the current study, a rabbit model with moderately
hypercholesterolemia was established by feeding a chol-
esterol diet. The effect of statins combined with probucol
and cilostazol on atherosclerosis was investigated. We
found that combined drug treatment significantly attenu-
ated atherosclerosis through inhibiting anti-inflammatory
and antioxidant properties independent of the lipid-
lowering function.Materials and methods
Animals and diets
Thirty Japanese white rabbits (male, 4-mon) were
supplied by Vital River Laboratories, Beijing, China.
The rabbits were randomly divided into three groups:
vehicle group (n = 10); atorvastatin group (0.005 %
atorvastatin, n = 10); and APC group (0.005 % atorva-
statin + 0.3 % probucol + 0.3 % cilostazol, n = 10). AllFig. 1 Plasma lipid levels. Plasma cholesterol total cholesterol (TC) (a), low-
high-density lipoprotein cholesterol (HDL-C) levels (d) were measured ever
group. **P < 0.01 vs. vehicle or statin treatment grouprabbits were fed a cholesterol diet containing 0.3 %
cholesterol and 3 % soybean oil for 12 weeks.
The probucol and cilostazol were provided by
Otsuka Pharmaceutical Co., Ltd. Tokushima, Japan.
Atorvastatin calcium was purchased from Sequoia
Research Products Ltd, Pangbourne, UK. The drugs
were mixed with cholesterol diets and prepared by Ke’ao
Xieli Diet Co., Ltd., Beijing, China. The drug concentra-
tions in diet were measured using gas chromatography or
high-performance liquid chromatographic methods as
previously described [21, 22]. All rabbits were given a
restricted diet (100 g/rabbit per day) and free access
to water. The animal experiments were approved by
the Laboratory Animal Administration Committee of
Xi’an Jiaotong University and carried out according
to the Guidelines for Animal Experimentation of
Xi’an Jiaotong University and the Guide for the Care
and Use of Laboratory Animals published by the US
National Institutes of Health (NIH Publication NO.
85–23, revised 2011).density lipoprotein cholesterol (LDL-C) (b), triglyceride (TG) (c), and
y 2 or 4 weeks. Data are expressed as the mean ± SEM, n = 10 for each
Table 1 Drug concentrations in diet from each group
Group Atorvastatin Probucol Cilostazol
Vehicle - - -
Atorvastatin 0.0037 % - -
APC 0.0039 % 0.2654 % 0.2491 %
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biochemical parameters
Blood samples were collected from the ear artery
using an EDTA anticoagulant tube after 16 h fasting.
Plasma was obtained after centrifuging at 3000 rpm
for 20 min. The plasma triglycerides (TG), total
cholesterol (TC), high-density lipoprotein cholesterol
(HDL-C) and low-density lipoprotein cholesterol
(LDL-C) were determined by commercial assay kits
(Biosino Bio-technology and Science Inc., Beijing,
China). Plasma TC and TG levels were measured bi-
weekly, while plasma HDL-C and LDL-C levels were
measured every 4 weeks. In order to compare whole
plasma lipid levels in 12 weeks among three groups, the
incremental area under the curve (AUC) was calculated
according to the trapezium rule [23].
The C-reactive protein (CRP) levels were quanti-
fied using an ELISA kit (Immunology Consultants
Laboratory, Inc., Newberg, OR, USA). The plasma
levels of superoxide dismutase (SOD) and malondial-
dehyde (MDA) were measured by xanthine oxidase
assay and thiobarbituric acid assay kits (Nanjing
Jiancheng Bioengineering Institute, Nanjing, China),
respectively, and oxidized LDL (ox-LDL) was mea-
sured by an ELISA kit (R&D Systems, Minneapolis,
MN,USA).Fig. 2 Aortic atherosclerotic lesions. Aortic trees were stained with Sudan I
Data are expressed as the mean ± SEM, n = 10 for each group. *P < 0.05, **PQuantification of gross atherosclerotic lesions
At the end of the experiment, all rabbits were eutha-
nized by intravenous injection of an overdose of sodium
pentobarbital. Rabbit aortas were subsequently col-
lected for analysis of the aortic lesions. Aortic en face
atherosclerosis was evaluated after the aortic trees were
stained with Sudan IV as previously described [24].
Sudanophilic area was quantified using image analysis
software (WinROOF Ver.6.5, Mitani Co., Ltd., Fukui,
Japan) and expressed as a percentage of the aorta.
Histology and immunohistochemistry
For the microscopic quantification of lesions, the aortic
arch of each rabbit was cut into 8 to 10 sections (4 μm)
as previously described [25]. To evaluate the micro-
scopic lesion area of each aorta, all sections were stained
with hematoxylin and eosin (HE), and measured by the
image analysis system described above. For microscopic
evaluation of cellular components in the lesions, serialV (a) and the lesion area was calculated in different parts of aorta (b).
< 0.01 vs. vehicle or statin treatment group
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cally stained with the following antibodies (Abs) against
macrophage (MФ) (RAM11, Dako, Carpinteria, CA,
USA) and smooth muscle cells (SMC) (α-smooth muscle
actin, Thermo Fisher Scientific Pierce, Rockford, IL,
USA). Secondary Abs included anti-murine IgG (Beijing
Zhongshan Biotechnology, Beijing, China) for MФ and
SMC staining [25].
Lesion type and quantitation
We analyzed whether the combined drug treatment had
any effect on the progression of atherosclerosis accord-
ing to American Heart Association guidelines in which
atherosclerotic lesions are divided into I-VI morpho-
logically characteristic types [26, 27]. To quantify lesion
types, the total length of each lesion in the aortic arch
was calculated in three groups using a method as re-
ported in our previous study [28].Fig. 3 Histological analysis of aortic atherosclerosis. Representative microgr
morphometric analysis of intimal lesions, lesion positive area of macrophag
expressed as the mean ± SEM, n = 10 for each group. *P < 0.05, **P < 0.01 vStatistical analysis
The statistical analyses were carried out by one-way
ANOVA followed by LSD test using the SPSS 13.0 soft-
ware. In all cases, data were expressed as the mean ±




As shown in Fig. 1, the plasma levels of TC, LDL-C and
TG were not significantly different among three groups,
while the HDL-C level was significantly lower in APC
group than vehicle and statin groups, respectively. Over-
all, in this study, statin and APC treatment did not affect
plasma TC and TG levels.
The drug concentrations in each diet were confirmed by
gas chromatography or high-performance liquid chroma-
tographic as shown in Table 1. There was no difference inaphs of the intimal lesions and cellular components (a) and
e (MФ) and smooth muscle cells (SMCs) in these lesions (b). Data are
s. vehicle or statin treatment group
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shown).Gross lesion of aortic atherosclerosis
In this experiment, even in the absence of a significant
lipid-lowering effect, both statin and APC treatment led
to a significant decrease in atherosclerotic gross lesions.
Total atherosclerotic gross lesions were notably reduced
by 85 % in APC treatment (P < 0.01) and 74 % in statin
(P < 0.05) compared with vehicle (Fig. 2a and b). A simi-
lar reduction was found in all parts of the aortic tree, in-
cluding the aortic arch, thoracic and abdominal aortas in
APC compared to vehicle and statin groups (Fig. 2a and
b). Apparently, the anti-atherogenic effect of combined
triple drug therapy was efficacious than statin alone.
Furthermore, this anti-atherogenic effect was not
dependent of the lipid-lowering function of statins.Histological examination
To quantify the size and components of atherosclerotic le-
sions, we measured the aortic arch sections using patho-
logical analysis. Histological and immunohistochemical
studies revealed that the intimal lesions and the positive
area of MФ and SMC in statin group were reduced com-
pared with the vehicle (Fig. 3). APC treatment significantly
decreased the intimal lesions and the positive area of MФ
and SMC compared with the vehicle (P < 0.05 or P < 0.01).
Importantly, we found that the intimal lesions and the
positive area of MФ and SMC in the APC group were fur-
ther reduced compared with statin group (P < 0.05) (Fig. 3).
These results suggest that APC treatment is moreFig. 4 Lesions type analysis. Lesion types of the aortic arch were analyzed
respectively (b). Data are expressed as the mean ± SEM, n = 10 for each groefficacious in inhibiting the intimal lesions and MФ and
SMCs than stain treatment alone.
Lesion type analysis
We further quantified the lesion types of the aortic arch
in each group. We found that atherosclerotic lesions in
cholesterol-fed rabbits were composed of type I, II and
III lesions (Fig. 4). Although all types of lesions were re-
duced in both statin and APC groups, statistical signifi-
cance was only found in APC group compared with the
vehicle group (Fig. 4). Type III represents the stage that
links type II to advanced lesions [26, 27].
Inflammatory and oxidation markers
To explore the possible mechanisms underlying APC
anti-atherogenic effects, we measured plasma levels of
SOD, MDA, ox-LDL and CRP at 12 weeks. As shown in
Fig. 5, plasma SOD levels were significantly increased in
the APC group (P = 0.04), while plasma MDA (even
though not statistically different), ox-LDL and CRP levels
were reduced in both APC and statin groups compared to
vehicle (Fig. 5a-d).
Discussion
Risk factors for atherosclerosis, such as dyslipidemia, in-
flammation, oxidative stress, abnormal levels of coagu-
lant and central obesity often co-exist [29]. The present
study provides evidence that the combined drug therapy
consisting of probucol, cilostazol and atorvastatin markedly
enhances the statin anti-atherogenic effect independent of a
lipid-lowering manner in moderately hypercholesterolemic
rabbit model.by microscope in each group (a). Lesion types I-III was quantified,
up. *P < 0.05 vs. vehicle
Fig. 5 Oxidative stress and inflammation markers. Plasma superoxide dismutase (SOD) (a), malonaldehyde (MDA) (b), oxidized low-density lipoprotein
(ox-LDL) (c) and C-reactive protein (CRP) levels (d) were measured at 12 weeks. Data are expressed as the mean ± SEM, n = 8 or 10 for each group. *P
< 0.05, **P < 0.01 vs. vehicle or statin treatment group
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cholesterolemia (plasma TC = 350–500 mg/dl) compared
to our previous studies (rabbit plasma TC = 800–1200
mg/dl) [19, 24, 25, 30, 31]. We used this model to investi-
gate the effect of combined drug treatment in the early
stages of atherosclerosis and found that, except for HDL-
C, plasma lipids were not affected after 12 weeks of drug
treatment. This was possibly due to the “relatively low”
hypercholesterolemia baseline in these rabbits. However,
APC treated group had lower HDL-C levels, which was
caused by the presence of probucol. In spite of this, HDL
functions were not impaired but were actually more ef-
ficient for reverse cholesterol transport(RCT) [32–35].
Previous studies have revealed that cholesterol ester
transfer protein (CETP) plays a crucial role in mediat-
ing HDL functions and probucol may enhance reverse
cholesterol transport by increasing CETP expression.
HDLs mediated by enhanced CETP activity showed po-
tentially anti-atherogenic functions [34]. In our previ-
ous study, we measured hepatic LDL receptor, SR-B1,ABCA1, CETP mRNA and protein expression levels
and found that all drug treatment groups significantly
increased hepatic LDL receptor mRNA expression by
which hepatic uptake of LDLs would be enhanced (data
not shown). Interestingly, we found combination treat-
ment synergistically increased CETP mRNA and protein
expression level in liver (data not shown). CETP as a
plasma glycoprotein transfers CE from HDL to apoB-
containing lipoproteins in exchange for triglycerides.
Thus, directly through hepatic SR-B1 receptor uptake or
indirectly through transfer of HDL-CE to ApoB-containing
lipoproteins with subsequent receptor-mediated hepatic
uptake, CETP could contribute significantly to the RCT
pathway [36, 37].
Statins dramatically reduced cardiovascular events in pa-
tients with normal lipid levels or without established
ASCVD, independently from lipid-lowering properties [38].
Moreover, plasma cholesterol lowering does not necessarily
lead to protection against cardiovascular disease. In the
present study, the attenuation of atherosclerotic lesions in
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tion. These findings may be consistent with the “Mevalo-
nate hypothesis” proposed recently [39] and further
studies are needed for verifying. The anti-atherosclerosis in
APC treatment may be due to their multiple pharmaco-
logical properties, such as enhanced anti-inflammatory and
anti-oxidant effects in APC treatment group. Elevations in
inflammatory markers, such as CRP, prospectively define
the risk of atherosclerotic complications [31, 40, 41]. In the
present study, plasma levels of CRP and ox-LDL were not-
ably reduced in APC treated group compared to vehicle.
Furthermore, SOD levels were significantly increased, while
MDA levels simultaneously decreased in the APC treated
group compared to vehicle. Statins as well as cilostazol, also
known as platelet-activating factor inhibitors, play an im-
portant role in the crosstalk of dyslipidemia, inflammation
and atherogenesis [42–46]. In the moderate hypercholester-
olemia rabbit model, we found that combination treatment
(statins, cilostazol and probucol) decreases atherogenesis
via pleiotropic effects, such as anti-inflammation, anti-
oxidation and inhibition of platelet-activating factor.
Although it remains to be verified clinically whether
combined APC treatment exhibits a “potent anti-
atherogenic function”, it seems that APC more strongly
attenuates the progression of atherosclerosis than statin
alone in cholesterol-fed rabbits. These insights may pro-
vide us with a new concept with which to effectively
delay the occurrence of cardiovascular events by APC
combined drug treatment in the early stages for those
patients with or without established ASCVD.Competing interests
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